ianalumab
Sponsor Novartis AG · listed as NVS
ianalumab is a drug asset sponsored by Novartis AG, listed as NVS. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Mar 26, 2027 (day precision, medium confidence), tied to trial NCT05639114. That trial is in Phase 3 and currently active not recruiting, studying Systemic Lupus Erythematosus. It appears across 4 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for ianalumab
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-03-26 | READOUT | medium | NCT05639114 |
| 2027-04-12 | READOUT | medium | NCT05624749 |
Trials for ianalumab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05639114 catalyst | Phase 3 | Active, not recruiting | 2027-03-26 | Experimental | Novartis Pharmaceuticals | Systemic Lupus Erythematosus |
| NCT05624749 catalyst | Phase 3 | Active, not recruiting | 2027-04-12 | Experimental | Novartis Pharmaceuticals | Systemic Lupus Erythematosus |
| NCT06133972 | Phase 3 | Recruiting | 2034-04-03 | Experimental | Novartis Pharmaceuticals | Systemic Lupus Erythematosus |
| NCT06711887 | Phase 3 | Recruiting | 2035-08-01 | Experimental | Novartis Pharmaceuticals | Lupus Nephritis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More NVS catalysts